Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1993 Dec;61(12):5214–5218. doi: 10.1128/iai.61.12.5214-5218.1993

Prevention of renal scarring from pyelonephritis in nonhuman primates by vaccination with a synthetic Escherichia coli serotype O8 oligosaccharide-protein conjugate.

J A Roberts 1, M B Kaack 1, G Baskin 1, S B Svenson 1
PMCID: PMC281303  PMID: 8225595

Abstract

Rhesus monkeys were vaccinated with a synthetic Escherichia coli serotype O8 oligosaccharide-protein conjugate. Using our experimental pyelonephritis monkey model, we tested whether such immunization was protective against the renal damage from inflammation following experimental infection with a P-fimbriated O-antigenically homologous E. coli strain. The vaccination did not significantly alter the duration of bacteriuria or interfere with the infection. However, the vaccine was efficient in renal protection, as vaccinated animals showed significantly less intratubular infiltration of neutrophils (P < 0.02) and the degree of renal scarring was also significantly less in these animals (P > 0.005) than in the control animals. Total kidney involvement in the vaccinated animals was 16.9%, compared with 32.5% in the control animals (P = 0.07).

Full text

PDF
5214

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdelnoor A. M., Johnson A. G., Anderson-Imbert A., Nowotny A. Immunization against bacteria- and endotoxin-induced hypotension. Infect Immun. 1981 Jun;32(3):1093–1099. doi: 10.1128/iai.32.3.1093-1099.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baumgartner J. D., Glauser M. P., McCutchan J. A., Ziegler E. J., van Melle G., Klauber M. R., Vogt M., Muehlen E., Luethy R., Chiolero R. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet. 1985 Jul 13;2(8446):59–63. doi: 10.1016/s0140-6736(85)90176-x. [DOI] [PubMed] [Google Scholar]
  3. Billiau A., Vandekerckhove F. Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock. Eur J Clin Invest. 1991 Dec;21(6):559–573. doi: 10.1111/j.1365-2362.1991.tb01410.x. [DOI] [PubMed] [Google Scholar]
  4. Jansson P. E., Lönngren J., Widmalm G., Leontein K., Slettengren K., Svenson S. B., Wrangsell G., Dell A., Tiller P. R. Structural studies of the O-antigen polysaccharides of Klebsiella O5 and Escherichia coli O8. Carbohydr Res. 1985 Dec 15;145(1):59–66. doi: 10.1016/s0008-6215(00)90412-9. [DOI] [PubMed] [Google Scholar]
  5. Kaack M. B., Pere A., Korhonen T. K., Svenson S. B., Roberts J. A. P-fimbriae vaccines. I. Cross reactive antibodies to heterologous P-fimbriae. Pediatr Nephrol. 1989 Oct;3(4):386–390. doi: 10.1007/BF00850212. [DOI] [PubMed] [Google Scholar]
  6. Kaack M. B., Roberts J. A., Baskin G., Patterson G. M. Maternal immunization with P fimbriae for the prevention of neonatal pyelonephritis. Infect Immun. 1988 Jan;56(1):1–6. doi: 10.1128/iai.56.1.1-6.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lindberg A. A., Greisman S. E., Svenson S. B. Induction of endotoxin tolerance with nonpyrogenic O-antigenic oligosaccharide-protein conjugates. Infect Immun. 1983 Sep;41(3):888–895. doi: 10.1128/iai.41.3.888-895.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. McCabe W. R. ENDOTOXIN TOLERANCE. I. ITS INDUCTION BY EXPERIMENTAL PYELONEPHRITIS. J Clin Invest. 1963 May;42(5):610–617. doi: 10.1172/JCI104751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. NOLL H., BRAUDE A. I. Preparation and biological properties of a chemically modified Escherichia coli endotoxin of high immunogenic potency and low toxicity. J Clin Invest. 1961 Nov;40:1935–1951. doi: 10.1172/JCI104419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Nowotny A., Behling U. H., Chang H. L. Relation of structure to function in bacterial endotoxins. VIII. Biological activities in a polysaccharide-rich fraction. J Immunol. 1975 Jul;115(1):199–203. [PubMed] [Google Scholar]
  11. Pryor J. L., Jenkins A. D. Use of double-pigtail stents in extracorporeal shock wave lithotripsy. J Urol. 1990 Mar;143(3):475–478. doi: 10.1016/s0022-5347(17)39993-7. [DOI] [PubMed] [Google Scholar]
  12. Roberts J. A. Etiology and pathophysiology of pyelonephritis. Am J Kidney Dis. 1991 Jan;17(1):1–9. doi: 10.1016/s0272-6386(12)80242-3. [DOI] [PubMed] [Google Scholar]
  13. Roberts J. A., Hardaway K., Kaack B., Fussell E. N., Baskin G. Prevention of pyelonephritis by immunization with P-fimbriae. J Urol. 1984 Mar;131(3):602–607. doi: 10.1016/s0022-5347(17)50513-3. [DOI] [PubMed] [Google Scholar]
  14. Roberts J. A., Kaack B., Källenius G., Möllby R., Winberg J., Svenson S. B. Receptors for pyelonephritogenic Escherichia coli in primates. J Urol. 1984 Jan;131(1):163–168. doi: 10.1016/s0022-5347(17)50251-7. [DOI] [PubMed] [Google Scholar]
  15. Roberts J. A., Kaack M. B., Baskin G., Korhonen T. K., Svenson S. B., Winberg J. P-fimbriae vaccines. II. Cross reactive protection against pyelonephritis. Pediatr Nephrol. 1989 Oct;3(4):391–396. doi: 10.1007/BF00850213. [DOI] [PubMed] [Google Scholar]
  16. Roberts J. A., Roth J. K., Jr, Domingue G., Lewis R. W., Kaack B., Baskin G. Immunology of pyelonephritis in the primate model. V. Effect of superoxide dismutase. J Urol. 1982 Dec;128(6):1394–1400. doi: 10.1016/s0022-5347(17)53516-8. [DOI] [PubMed] [Google Scholar]
  17. Roberts J. A., Roth J. K., Jr, Domingue G., Lewis R. W., Kaack B., Baskin G. Immunology of pyelonephritis in the primate model. VI. Effect of complement depletion. J Urol. 1983 Jan;129(1):193–196. doi: 10.1016/s0022-5347(17)51981-3. [DOI] [PubMed] [Google Scholar]
  18. Roberts J. A., Suarez G. M., Kaack B., Kallenius G., Svenson S. B. Experimental pyelonephritis in the monkey. VII. Ascending pyelonephritis in the absence of vesicoureteral reflux. J Urol. 1985 Jun;133(6):1068–1075. doi: 10.1016/s0022-5347(17)49382-7. [DOI] [PubMed] [Google Scholar]
  19. Schlegel J. U., Hamway S. A. Individual renal plasma flow determination in 2 minutes. J Urol. 1976 Sep;116(3):282–285. doi: 10.1016/s0022-5347(17)58783-2. [DOI] [PubMed] [Google Scholar]
  20. Svenson S. B., Lindberg A. A. Artificial Salmonella vaccines. Prog Allergy. 1983;33:120–143. doi: 10.1159/000407424. [DOI] [PubMed] [Google Scholar]
  21. Svenson S. B., Lindberg A. A. Coupling of acid labile Salmonella specific oligosaccharides to macromolecular carriers. J Immunol Methods. 1979;25(4):323–335. doi: 10.1016/0022-1759(79)90025-5. [DOI] [PubMed] [Google Scholar]
  22. Svenson S. B., Lindberg A. A. Immunochemistry of Salmonella O-antigens: preparation of an octasaccharide-bovine serum albumin immunogen representative of Salmonella serogroup B O-antigen and characterization of the antibody response. J Immunol. 1978 May;120(5):1750–1757. [PubMed] [Google Scholar]
  23. Svenson S. B., Nurminen M., Lindberg A. A. Artificial Salmonella vaccines: O-antigenic oligosaccharide-protein conjugates induce protection against infection with Salmonella typhimurium. Infect Immun. 1979 Sep;25(3):863–872. doi: 10.1128/iai.25.3.863-872.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Väisänen-Rhen V., Elo J., Väisänen E., Siitonen A., Orskov I., Orskov F., Svenson S. B., Mäkelä P. H., Korhonen T. K. P-fimbriated clones among uropathogenic Escherichia coli strains. Infect Immun. 1984 Jan;43(1):149–155. doi: 10.1128/iai.43.1.149-155.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES